Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference

Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates in Elderly and Obese Patients Additional VIBATIV Study Results Demonstrate Greater in vitro Potency than Competitor Antibiotics Against Difficult-to-Treat Staphylococcus aureus Pathogens including Challenging


Leave a Reply

Your email address will not be published.